Literature DB >> 1416910

Baculovirus expressed herpes simplex virus type 1 glycoprotein C protects mice from lethal HSV-1 infection.

H Ghiasi1, R Kaiwar, A B Nesburn, S L Wechsler.   

Abstract

A recombinant baculovirus (vAc-gC1) was constructed that expresses the glycoprotein C (gC) gene of herpes simplex virus type 1 (HSV-1). When Sf9 cells were infected with this recombinant, a protein that was smaller in size than authentic HSV-1 gC was detected by Western blotting using anti-gC polyclonal antibody. The recombinant gC was susceptible to tunicamycin, partially resistant to Endo-H, and was found on the membrane of Sf9 cells. Antibodies raised in mice to recombinant gC reacted with gC from HSV-1 infected cells and neutralized the infectivity of HSV-1 in vitro. Immunized mice were protected from lethal challenge with HSV-1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416910     DOI: 10.1016/0166-3542(92)90062-a

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  10 in total

1.  Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits.

Authors:  A B Nesburn; S Slanina; R L Burke; H Ghiasi; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

2.  Production of herpes B virus recombinant glycoproteins and evaluation of their diagnostic potential.

Authors:  Ludmila Perelygina; Irina Patrusheva; Soumya Hombaiah; Holley Zurkuhlen; Martin J Wildes; Nikolai Patrushev; Julia Hilliard
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

3.  Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits.

Authors:  A B Nesburn; R L Burke; H Ghiasi; S Slanina; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

4.  Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.

Authors:  Shaohui Wang; Alexander V Ljubimov; Ling Jin; Klaus Pfeffer; Mitchell Kronenberg; Homayon Ghiasi
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

5.  Expression of equine herpesvirus 1 glycoprotein D by using a recombinant baculovirus.

Authors:  D N Love; C W Bell; D Pye; S Edwards; M Hayden; G L Lawrence; D Boyle; T Pye; J M Whalley
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

6.  Immunization with glycoprotein C of equine herpesvirus-1 is associated with accelerated virus clearance in a murine model.

Authors:  D Tewari; S V Nair; M C De Ungria; G L Lawrence; M Hayden; D N Love; H J Field; J M Whalley
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

7.  Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K.

Authors:  H Ghiasi; S Slanina; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

8.  Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.

Authors:  H Ghiasi; R Kaiwar; A B Nesburn; S Slanina; S L Wechsler
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

9.  Overexpression of herpes simplex virus glycoprotein K (gK) alters expression of HSV receptors in ocularly-infected mice.

Authors:  Sariah J Allen; Kevin R Mott; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-15       Impact factor: 4.799

Review 10.  Role of Herpes Simplex Virus Type 1 (HSV-1) Glycoprotein K (gK) Pathogenic CD8+ T Cells in Exacerbation of Eye Disease.

Authors:  Ujjaldeep Jaggi; Shaohui Wang; Kati Tormanen; Harry Matundan; Alexander V Ljubimov; Homayon Ghiasi
Journal:  Front Immunol       Date:  2018-12-07       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.